Compare Ginkgo Bioworks Holdings Inc (DNA) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Enbridge Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.12 (market cap $590.53M), while Enbridge Inc trades at $56.39 (market cap $121.05B). The key difference: Enbridge Inc is far larger — about 205× Ginkgo Bioworks Holdings Inc's market cap, and Enbridge Inc pays a 5.03% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ENB | |
|---|---|---|
Market Cap | $590.53M | $121.05B |
Sector | Health | Energy |
52-Week High | $16.14 | $58.04 |
52-Week Low | $5.48 | $44.59 |
Enterprise Value | $627.78M | $201.85B |
Dividend Yield | — | 5.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Enbridge (ENB) trades at $55.07, up 0.75% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $65.19 billion in 2025, with net income of $7.49 billion, though it missed Q3 2025 EPS estimates. Analyst sentiment is balanced with a 48% buy rating, and the stock offers a dividend yield supported by over $28 billion in growth projects. Recent news highlights its role in energy infrastructure and AI-driven power demand.
Outlook is cautiously optimistic due to solid cash flow and dividend sustainability, but risks include high debt levels and sensitivity to energy markets. The stock presents a value opportunity for income-focused investors, with earnings on July 31, 2026, as a key near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
